These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 1521204)

  • 21. Bone marrow transplantation in beta-thalassemia major with prevention of graft-vs-host disease.
    Slavin S; Or R; Cividalli G; Brautbar C; Hale G; Waldmann H; Rachmilewitz E
    Birth Defects Orig Artic Ser; 1988; 23(5B):313-6. PubMed ID: 3291967
    [No Abstract]   [Full Text] [Related]  

  • 22. Use of lymphokine-activated killer cells to prevent bone marrow graft rejection and lethal graft-vs-host disease.
    Azuma E; Yamamoto H; Kaplan J
    J Immunol; 1989 Sep; 143(5):1524-9. PubMed ID: 2668409
    [TBL] [Abstract][Full Text] [Related]  

  • 23. T-cell depletion to prevent graft-versus-host disease after bone marrow transplantation.
    Champlin R
    Hematol Oncol Clin North Am; 1990 Jun; 4(3):687-98. PubMed ID: 2193019
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transfusion effect on graft-versus-host disease and leukemic relapse in HLA-matched bone marrow transplantation.
    de Gast GC; Beatty PG; Amos D; Sullivan K; Anderson JE; Thomas ED; Hansen JA
    Transplant Proc; 1987 Feb; 19(1 Pt 3):2700. PubMed ID: 3274581
    [No Abstract]   [Full Text] [Related]  

  • 25. Successful treatment with thalidomide of acute graft-versus-host disease after bone-marrow transplantation.
    Lim SH; McWhannell A; Vora AJ; Boughton BJ
    Lancet; 1988 Jan; 1(8577):117. PubMed ID: 2891954
    [No Abstract]   [Full Text] [Related]  

  • 26. Use of cyclosporine for prevention of graft-versus-host disease after allogeneic bone marrow transplantation.
    Gluckman E; Devergie A; Lokiec F
    Transplant Proc; 1988 Jun; 20(3 Suppl 3):461-9. PubMed ID: 3291282
    [No Abstract]   [Full Text] [Related]  

  • 27. [Prevention of graft versus host disease by in vitro immunodepletion of the graft].
    Maraninchi D
    Nouv Rev Fr Hematol (1978); 1985; 27(6):349-50. PubMed ID: 3912729
    [No Abstract]   [Full Text] [Related]  

  • 28. Sclerodermatous chronic graft-versus-host disease--a report of four pediatric cases.
    Tolland JP; Devereux C; Jones FC; Bingham EA
    Pediatr Dermatol; 2008; 25(2):240-4. PubMed ID: 18429789
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The use of monoclonal antibodies in human bone marrow transplantation.
    Neudorf SM; Filipovich AH; Kersey JH
    Prog Clin Biol Res; 1984; 149():367-77. PubMed ID: 6377327
    [No Abstract]   [Full Text] [Related]  

  • 30. [Prophylaxis of acute graft-versus-host disease after allogeneic bone marrow transplantation--combination protocol of high dose methylprednisolone, prednisolone and methotrexate].
    Shinohara Y; Kai S; Misawa M; Fujimori Y; Okamoto T; Kohsaki M; Kanamaru A; Ifuku H; Ohe Y; Hara H
    Rinsho Ketsueki; 1986 Jan; 27(1):30-5. PubMed ID: 3520045
    [No Abstract]   [Full Text] [Related]  

  • 31. Response to thalidomide therapy in refractory chronic graft-versus-host disease.
    Browne PV; Weisdorf DJ; DeFor T; Miller WJ; Davies SM; Filipovich A; McGlave PB; Ramsay NK; Wagner J; Enright H
    Bone Marrow Transplant; 2000 Oct; 26(8):865-9. PubMed ID: 11081386
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bone marrow transplantation. Current limitations and future utilization.
    Gardner RV; Gross S
    J Fla Med Assoc; 1984 May; 71(5):316-20. PubMed ID: 6376695
    [No Abstract]   [Full Text] [Related]  

  • 33. Prevention of graft-versus-host disease after bone marrow and small bowel transplantation by ultraviolet B modulation of bone marrow cells.
    Chowdhury NC; Jin MX; Hardy MA; Oluwole SF
    Transplant Proc; 1993 Feb; 25(1 Pt 1):475-6. PubMed ID: 8438384
    [No Abstract]   [Full Text] [Related]  

  • 34. Bone marrow transplantation and graft-versus-host disease.
    Powles RL
    Curr Opin Immunol; 1989-1990; 2(6):870-5. PubMed ID: 2486567
    [No Abstract]   [Full Text] [Related]  

  • 35. Immunosuppression, graft-versus-host disease, and infection after bone marrow transplantation.
    Kramer BS; Elfenbein GJ
    J Fla Med Assoc; 1984 May; 71(5):321-8. PubMed ID: 6429272
    [No Abstract]   [Full Text] [Related]  

  • 36. Role of immunosuppressive drugs for prevention of graft-v-host disease after human HLA matched bone marrow transplantation.
    Gluckman E; Devergie A; Lokiec F; Traineau R; Cosset JM; Lemercier N; Varrin F; Cavazzana M; de Castro H; Meletis J
    Transplant Proc; 1987 Dec; 19(6 Suppl 7):61-5. PubMed ID: 3321648
    [No Abstract]   [Full Text] [Related]  

  • 37. Separation of graft-vs.-host disease and graft-vs.-leukemia effect against chronic myelogenous leukemia.
    Champlin R
    Exp Hematol; 1995 Oct; 23(11):1148-51. PubMed ID: 7556522
    [No Abstract]   [Full Text] [Related]  

  • 38. Approaches to graft-versus-host disease following bone marrow transplantation in monkeys and man.
    Dicke KA; Spitzer G; Peters L; Stevens EE; Hendriks W; McCredie tkb
    Transplant Proc; 1978 Mar; 10(1):217-21. PubMed ID: 416529
    [No Abstract]   [Full Text] [Related]  

  • 39. The influence of the microbial flora on incidence of graft-versus-host disease in human allogeneic bone marrow transplantation.
    Schmeiser T; Kurrle E; Arnold R; Heit W; Krieger D; Kubanek B; Heimpel H
    Prog Clin Biol Res; 1985; 181():433-5. PubMed ID: 3895247
    [No Abstract]   [Full Text] [Related]  

  • 40. [1st seminar of the Study Group on Bone Marrow Grafting on immunodepletion in the prevention of the graft-vs-host reaction. Marseilles, France, 4-6 October 1984. Abstracts].
    Nouv Rev Fr Hematol (1978); 1985; 27(6):351-75. PubMed ID: 3912730
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.